JPS625153B2 - - Google Patents

Info

Publication number
JPS625153B2
JPS625153B2 JP53100372A JP10037278A JPS625153B2 JP S625153 B2 JPS625153 B2 JP S625153B2 JP 53100372 A JP53100372 A JP 53100372A JP 10037278 A JP10037278 A JP 10037278A JP S625153 B2 JPS625153 B2 JP S625153B2
Authority
JP
Japan
Prior art keywords
formula
water
acid
oxoxanthene
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP53100372A
Other languages
Japanese (ja)
Other versions
JPS5527163A (en
Inventor
Kazuhiro Onoki
Hisashi Kunieda
Kyoshi Kawamura
Naoki Machida
Shozo Shirato
Masahiko Nagakura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Original Assignee
Kowa Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co Ltd filed Critical Kowa Co Ltd
Priority to JP10037278A priority Critical patent/JPS5527163A/en
Publication of JPS5527163A publication Critical patent/JPS5527163A/en
Publication of JPS625153B2 publication Critical patent/JPS625153B2/ja
Granted legal-status Critical Current

Links

Description

【発明の詳細な説明】[Detailed description of the invention]

本発明は新規なテトラヒドロキサンテン−2−
カルボン酸誘導体、更に詳細には次の一般式
()、 〔式中、R1はニトロ基、カルボキシル基またはシ
アノ基を、R2は水素原子または低級アルキル基
を示す〕 で表わされるテトラヒドロキサンテン−2−カル
ボン酸誘導体に関する。 本発明の()式で表わされるテトラヒドロキ
サンテン−2−カルボン酸誘導体は、抗アレルギ
ー作用、抗炎症作用、鎮痛作用、PCA(Passive
Cutaneous Anaphylaxis)反応阻止作用を有し、
医薬品として有用な化合物である。 本発明の()式の化合物は、例えば次の反応
式に従つて、アシル化サリチル酸類()また
はそのカルボキシル基における反応性誘導体に
()式の化合物を反応させる方法、方法に
より得られた()式の化合物をニトロ化する方
法、方法により得られた()式のハロゲン
化物をシアン化する方法、あるいは方法によ
り得られた(c)式のシアン化物を加水分解す
る方法の何れかの方法によつて製造される。 (式中、Aは水素原子または低級アルキル基を示
し、R2は前記した意味を有する。また、R3はハ
ロゲン原子または水素原子を、R4は低級アルキ
ル基を、Xはハロゲン原子を示す) アシル化サリチル酸類のカルボキシル基におけ
る反応性誘導体としては酸無水物、酸ハロゲニド
等が挙げられ、例えばサリチル酸類()の水酸
基をアシル化して()式の化合物となし、次い
でこれにトリエチルアミン等の塩基の存在下クロ
ル炭酸エステルを反応せしめて混合酸無水物を得
ることができる。 式()の化合物と式()との反応は適当な
不活性溶媒、例えばジクロルメタン、クロロホル
ム、ベンゼン、トルエン、エーテル等の溶媒中室
温にて3〜5時間撹拌することによつておこなわ
れる。次いで反応液から溶媒を留去し、残留物に
ピリジン、ピロリジン等の塩基性水溶液または塩
酸、硫酸等の酸水溶液を加え、加熱還流すれば式
(a)の化合物が得られる。 式(a)の化合物中、R3が水素原子で表わ
される式()の化合物のニトロ化反応は例えば
硝酸、特に好ましくは硫酸−硝酸の混酸中で氷冷
下30分間撹拌することによりおこなわれる。次い
でクロロホルム、ジクロルメタン等の溶媒で抽出
し、水洗、乾燥し溶媒を留去し、残留物をニトロ
メタン等で結晶化させることにより式(b)の
化合物が得られる。 また、式(a)の化合物中、R3がハロゲン
原子で表わされる式()の化合物のシアン化反
応は例えばN−メチル−2−ピロリドン等の溶媒
中、シアン化第一銅等のシアン化試薬を加え、
160〜200℃で1〜3時間撹拌し、更に水−塩化第
二鉄−濃塩酸の混酸を加え、60〜100℃で30分間
撹拌し、一夜放置することによりおこなわれる。
生成した沈澱物は更に水洗、風乾、再結晶するこ
とにより式(c)の化合物が得られる。 この式(c)の化合物は更に必要に応じ、水
−硫酸−酢酸、水−硫酸等の酸性溶媒中で加水分
解反応をおこない式(d)の化合物とすること
ができる。 なお、上記方法により得られた化合物におい
て、Aが低級アルキル基である場合は、更にメタ
ノール、エタノール等の溶媒中、水酸化ナトリウ
ム、水酸化カリウム等のアルカリ触媒の存在下で
加水分解反応をおこなうことによりAが水素原子
で表わされる本発明化合物とすることができる。 〔薬理作用〕 次に斯くして得られた本発明化合物()につ
いて、以下の如くそのヒスタミン遊離反応抑制作
用及びPCA(Passive Culaneous Anaphylaxis)
反応抑制作用を調べた。この結果を第1表に示
す。 (試験方法) (1) ヒスタミン遊離反応抑制作用: 抗OAマウス血清(抗体価1:400〜1:
300)を20倍に生理食塩水にて希釈し、その5
mlを雄性SDラツト(体重300〜400g)に腹腔
内投与した。感作48時間後、放血にて動物を殺
し、ヘパリン(5units/ml)を含むタイロード
(Tyrode)液10mlを腹腔内に注入した。腹部を
1時間軽くマツサージした後腹腔液を採取し、
120×g5分間遠心して腹腔細胞を集めた。腹腔
細胞を106個/mlとなるようにタイロード溶液
で希釈し、その1.6mlを4分間プレインキユベ
ートした後、100μg/mlのOA溶液0.2mlおよ
び被検薬液0.2mlを加えて10分間インキユベー
トした。氷冷にて反応を停止後、120×g5分間
の遠心にて細胞層と上清に分離し、各々のヒス
タミン含量をグラントら(J.Immunol 117
450 1976参照)の方法に従い螢光法にて測定し
た。被検薬は、用時タイトロード溶液に溶解し
て用いた。結果は最少有効濃度(μg/ml)で
表わした。 (2) PCA反応抑制作用: 雄性SDラツト(体重300g以上)の背部を除
毛後、抗OAマウス血清の3段階の希釈液を0.1
ml/site皮内投与した。感作4時間後、エバン
ス・ブルー10mg/2mlおよびOA2mg/2mlを
含む抗原溶液を2ml/Kg静脈内投与し、その3
分後に各抗体希釈度に対する反応の有無につい
て判定した。判定には、各抗体希釈度に対し直
線性を有する範囲内で対照の長径×短径(mm2
が100〜150になる抗体希釈度を用い、次に示す
基準に従つて作用強度として示した。 −:抑制が全く認められないもの。 ±:抑制率が0〜25%で対照に対し有意差のな
いもの。 +:抑制率が25〜50%で対照に対し有意差のあ
るもの。 〓:抑制率が50〜75%で対照に対し有意差のあ
るもの。 〓:抑制率が75〜100%で対照に対し有意差の
あるもの。 被検薬は経口投与の場合、0.2%CMC溶液に
懸濁して抗原投与の1時間前に投与した。 (結果)
The present invention provides novel tetrahydroxanthene-2-
Carboxylic acid derivatives, more specifically the following general formula (), [In the formula, R 1 represents a nitro group, a carboxyl group, or a cyano group, and R 2 represents a hydrogen atom or a lower alkyl group]. The tetrahydroxanthene-2-carboxylic acid derivative represented by the formula () of the present invention has anti-allergic, anti-inflammatory, analgesic, and PCA (passive
Cutaneous Anaphylaxis) has a reaction inhibiting effect,
It is a compound useful as a medicine. The compound of the formula () of the present invention can be obtained by, for example, a method of reacting the compound of the formula () with an acylated salicylic acid () or a reactive derivative thereof at the carboxyl group, according to the following reaction formula ( A method of nitrating a compound of formula (), a method of cyanating a halide of formula () obtained by the method, or a method of hydrolyzing a cyanide of formula (c) obtained by the method. Manufactured by. (In the formula, A represents a hydrogen atom or a lower alkyl group, R 2 has the meaning described above, R 3 represents a halogen atom or a hydrogen atom, R 4 represents a lower alkyl group, and X represents a halogen atom. ) Reactive derivatives at the carboxyl group of acylated salicylic acids include acid anhydrides, acid halides, etc. For example, the hydroxyl group of salicylic acids () is acylated to form a compound of the formula (), and then triethylamine, etc. Mixed acid anhydrides can be obtained by reacting chlorocarbonate in the presence of a base. The reaction between the compound of formula () and formula () is carried out in a suitable inert solvent such as dichloromethane, chloroform, benzene, toluene, ether, etc. by stirring at room temperature for 3 to 5 hours. Next, the solvent is distilled off from the reaction solution, and a basic aqueous solution such as pyridine or pyrrolidine or an acid aqueous solution such as hydrochloric acid or sulfuric acid is added to the residue and the mixture is heated to reflux to obtain the compound of formula (a). Among the compounds of formula (a), the nitration reaction of the compound of formula () in which R 3 is a hydrogen atom is carried out, for example, by stirring in nitric acid, particularly preferably a mixed acid of sulfuric acid and nitric acid, for 30 minutes under ice cooling. . Next, the compound of formula (b) is obtained by extracting with a solvent such as chloroform or dichloromethane, washing with water, drying, distilling off the solvent, and crystallizing the residue with nitromethane or the like. In addition, among the compounds of formula (a), the cyanation reaction of the compound of formula () in which R 3 is a halogen atom can be carried out using cyanide such as cuprous cyanide in a solvent such as N-methyl-2-pyrrolidone. Add reagent,
This is carried out by stirring at 160 to 200°C for 1 to 3 hours, then adding a mixed acid of water, ferric chloride, and concentrated hydrochloric acid, stirring at 60 to 100°C for 30 minutes, and leaving it overnight.
The generated precipitate is further washed with water, air-dried, and recrystallized to obtain the compound of formula (c). This compound of formula (c) can be further subjected to a hydrolysis reaction in an acidic solvent such as water-sulfuric acid-acetic acid, water-sulfuric acid, etc. to form a compound of formula (d), if necessary. In addition, in the compound obtained by the above method, when A is a lower alkyl group, a hydrolysis reaction is further carried out in a solvent such as methanol or ethanol in the presence of an alkali catalyst such as sodium hydroxide or potassium hydroxide. This allows the compound of the present invention in which A is a hydrogen atom. [Pharmacological action] Next, regarding the thus obtained compound of the present invention (), its histamine release reaction inhibiting action and PCA (Passive Culaneous Anaphylaxis) were determined as follows.
The reaction inhibitory effect was investigated. The results are shown in Table 1. (Test method) (1) Histamine release reaction inhibitory effect: Anti-OA mouse serum (antibody titer 1:400-1:
300) was diluted 20 times with physiological saline, and
ml was administered intraperitoneally to male SD rats (body weight 300-400 g). Forty-eight hours after sensitization, the animals were sacrificed by exsanguination, and 10 ml of Tyrode's solution containing heparin (5 units/ml) was injected intraperitoneally. The abdominal cavity was lightly massaged for 1 hour, and the peritoneal fluid was collected.
Peritoneal cells were collected by centrifugation at 120×g for 5 minutes. Dilute peritoneal cells with Tyrode's solution to 10 6 cells/ml, pre-incubate 1.6 ml for 4 minutes, then add 0.2 ml of 100 μg/ml OA solution and 0.2 ml of test drug solution for 10 minutes. Incubated. After stopping the reaction on ice, the cell layer and supernatant were separated by centrifugation at 120 x g for 5 minutes, and the histamine content of each was determined according to Grant et al. (J. Immunol 117
450, 1976). The test drug was dissolved in Tightrode's solution before use. Results were expressed in minimum effective concentration (μg/ml). (2) PCA reaction inhibition effect: After removing hair from the backs of male SD rats (weighing 300 g or more), three dilutions of anti-OA mouse serum were applied to 0.1
Administered intradermally (ml/site). Four hours after sensitization, 2 ml/Kg of an antigen solution containing Evans Blue 10 mg/2 ml and OA 2 mg/2 ml was administered intravenously.
After a few minutes, the presence or absence of a reaction to each antibody dilution was determined. For determination, measure the long axis x short axis (mm 2 ) of the control within a linear range for each antibody dilution.
Using an antibody dilution that results in a value of 100 to 150, the potency was expressed as the potency according to the following criteria. −: No inhibition observed at all. ±: Suppression rate is 0 to 25%, with no significant difference from the control. +: Inhibition rate is 25 to 50% and significantly different from control. 〓: Inhibition rate is 50-75% and there is a significant difference from the control. 〓: Inhibition rate is 75-100% and there is a significant difference from the control. In the case of oral administration, the test drug was suspended in a 0.2% CMC solution and administered 1 hour before antigen administration. (result)

【表】【table】

【表】 この結果から明らかなように、本発明化合物は
比較化合物に比べ、10倍以上の抗アレルギー作用
を有する。 叙上の如く、本発明化合物はそれ自体医薬とし
て有用なものであるが、更に脱水素せしめれば抗
アレルギー作用なびに喘息治療作用を有するキサ
ンテン誘導体に導くこともできる。 次に実施例を挙げ説明する。 実施例 1 7−ニトロ−1・2・3・4−テトラヒドロ−
9−オキソキサンテン−2−カルボン酸メチル
エステル: 1・2・3・4−テトラヒドロ−9−オキソキ
サンテン−2−カルボン酸メチルエステル5.17g
の濃硫酸20ml中に氷冷下硝酸(d=1.38)5mlを
ゆつくり滴下し、滴下後30分間撹拌した。反応終
了後反応溶液を氷水中に投入し、クロロホルムで
抽出した。この抽出液を希炭酸水素ナトリウム溶
液で水洗、更に純水で水洗した。硫酸マグネシウ
ムで乾燥後溶媒を留去し残渣をニトロメタンより
再結晶し、融点163.5〜165℃を示す微黄色プリズ
ム晶の7−ニトロ−1・2・3・4−テトラヒド
ロ−9−オキソキサンテン−2−カルボン酸メチ
ルエステル7.40g(収率61.0%)を得た。 IR(νKBr naxcm-1):1730(−COO)、1640(−
C=
O)、1520、1340(−NO2) NMR(CDCl3)δ:8.95(1H、d、J=3Hz、C8
−H)、8.48、8.32(1H、d×2、J=3Hz、
C6−H)、7.45(1H、t、J=8Hz、C5
H)、3.74(3H、s、COOCH3)、3.06〜2.50
〔5H、m、(C1及びC3のCH2並びにC2のCH)〕、
2.50〜1.67〔2H、m、(C4のCH2)〕 元素分析値(C15H13NO6として): C H N 計算値(%) 59.40 4.32 4.62 実測値(%) 59.43 4.35 4.37 実施例 2 7−ニトロ−1・2・3・4−テトラ−9−オ
キソキサンテン−2−カルボン酸: 7−ニトロ−1・2・3・4−テトラヒドロ−
9−オキソキサンテン−2−カルボン酸メチルエ
ステル10.30gを、水酸化ナトリウム1.60gとと
もにメタノール120ml及び水40ml中に溶解し、2
時間加熱還流撹拌後、減圧下に溶媒留去し、残渣
に水を加え熱時過した。この液を塩酸で酸性
化することにより生成する析出晶を取し、水
洗、風乾後氷酢酸中より再結晶し、融点256〜
257.5℃を示す黄色プリズム晶の7−ニトロ−
1・2・3・4−テトラヒドロ−9−オキソキサ
ンテン−2−カルボン酸5.20g(収率52.9%)を
得た。 IR(νKBr naxcm-1):1740(−COOH)、1620(C

O)、1520、1340(−NO2) 元素分析値(C14H11NO6として); C H N 計算値(%) 58.13 3.83 4.84 実測値(%) 58.00 3.73 4.57 実施例 3 7−シアノ−1・2・3・4−テトラヒドロ−
9−オキソキサンテン−2−カルボン酸: 7−ブロモ−1・2・3・4−テトラヒドロ−
9−オキソキサンテン−2−カルボン酸22.62g
のN−メチル−2−ピロリドン溶液120ml中にシ
アン化第1銅12.54gを加え、190℃で2時間撹拌
し、放冷後塩化第二鉄49g、濃塩酸12ml及び水
73.5mlの混液を加え80℃で30分間撹拌し一夜放置
した。析出沈澱を水洗し、風乾後ジメチルフオル
ムアミド−エーテルにより再結晶し、融点274〜
276℃を示す白色葉状晶の7−シアノ−1・2・
3・4−テトラヒドロ−9−オキソキサンテン−
2−カルボン酸15.30g(収率81.3%)を得た。 IR(νKBr naxcm-1):2220(−CN)、1690(−
COOH)、1630(−C=O) 元素分析値(C15H11NO4として): C H N 計算値(%) 66.91 4.12 5.20 実測値(%) 66.45 4.16 5.42 MS(m/e):269〔M+〕 実施例 4 1・2・3・4−テトラヒドロ−9−オキソキ
サンテン−2・7−ジカルボン酸: 7−シアノ−1・2・3・4−テトラヒドロ−
9−オキソキサンテン−2−カルボン酸8.08gを
水−硫酸−酢酸(1:1:1)混液300ml中に加
え2時間加熱還流撹拌後放冷し、水300mlを加え
た。析出した白色沈澱を取し、水洗、風乾後ジ
メチルフオルムアミド−水により再結晶し、白色
粉末状の1・2・3・4−テトラヒドロ−9−オ
キソキサンテン−2・7−カルボン酸6.82g(収
率79.0%)を得た。 IR(νKBr naxcm-1):1710(−COOH)、1630(−

=O) 元素分析値(C15H12O6として): C H 計算値(%) 62.50 4.20 実測値(%) 62.19 4.17 MS(m/e):288〔M+〕 実施例 5 5−メチル−1・2・3・4−テトラヒドロ−
9−オキソキサンテン−2−カルボン酸メチル
エステル: (i) 3−メチルサリチル酸76.3gの無水酢酸溶液
160ml中に濃硫酸0.5gを加え、100℃で3時間
撹拌した。反応終了後反応液を氷水中に注入
し、クロロホルムで抽出した。この抽出液を水
洗、硫酸マグネシウムで乾燥し、更に溶媒を留
去した残油をベンゼン中より晶析させ、融点
112〜113.5℃を示す白色針状晶の3−メチルア
セチルサリチル酸71.3g(収率73.3%)を得
た。 IR(νKBr naxcm-1):1760(−COOH)、1690(

COO)、1230(−COO) NMR(CDCl3)δ:11.0(1H、s、COOH)、
8.06〜7.78(1H、m、Ar−H)、7.60〜7.03
(2H、m、Ar−H)、2.36〔3H、s、(C3
CH3)〕、2.26(3H、s、−OCOCH3) (ii) 3−メチルアセチルサリチル酸64.6gの無水
クロロホルム300mlを0℃以下に冷却し、まず
トリエチルアミン33.7gを滴下し、更に−5〜
10℃でエチルクロロフオルメート36.1g、次い
で1−ピロリジノシクロヘキセン−4−カルボ
ン酸メチル69.7gを滴下し後4時間撹拌して次
第に室温にもどす。減圧下で溶媒を留去し、残
渣にピリジン250ml及び水60mlを加え、1時間
加熱還流撹拌し、再び溶媒を留去した。更に残
渣に水600mlを加え、一夜放置後析出した沈澱
を取し、メタノールで洗浄し、淡黄色粉末を
得た。これをメタノール中で晶析させ、融点
152〜153℃で示す白色針状晶の5−メチル−
1・2・3・4−テトラヒドロ−9−オキソキ
サンテン−2−カルボン酸メチルエステル48.5
g(収率53.5%)を得た。 IR(νKBr naxcm-1):1720(−COO)、1640(
−C
=O) NMR(CDCl3)δ:8.02〜7.97(1H、m、Ar−
H)、7.62〜7.10(2H、m、Ar−H)、3.77
(3H、s、COOMe)、3.26〜1.67〔7H、m、
(C1、C3、C4のCH2及びC2のCH)〕、2.43
〔3H、s、(C5のCH3)〕 元素分析値(C16H16O4として): C H 計算値(%) 70.57 5.92 実測値(%) 70.83 5.88 MS(m/e):272〔M+〕 実施例 6 5−メチル−1・2・3・4−テトラヒドロ−
9−オキソキサンテン−2−カルボン酸: 5−メチル−1・2・3・4−テトラヒドロ−
9−オキソキサンテン−2−カルボン酸メチルエ
ステル27.2gを水酸化ナトリウム5.2gとともに
メタノール200ml中に溶解し、2時間加熱還流撹
拌後減圧下で溶媒留去し、残渣を水に溶解し、
過した。この液を10%塩酸で酸性化し、析出し
た白色沈澱を取し、水洗、風乾後、酢酸より再
結晶させ、融点238.5〜240℃で示す淡黄色プリズ
ム晶の5−メチル−1・2・3・4−テトラヒド
ロ−9−オキソキサンテン−2−カルボン酸21.9
g(収率84.7%)を得た。 IR(νKBr naxcm-1):1730(−COOH) NMR(CMSO−d6)δ:7.97〜7.11(3H、m、Ar
−H)、3.04〜1.43〔7H、m、C1、C3、C4
CH2及びC2のCH)〕、2.31(3H、s、CH3) 元素分析値(C15H14O4として): C H 計算値(%) 69.75 5.46 実測値(%) 69.79 5.43 MS(m/e):258〔M+〕、213〔M−COOH〕 実施例 7 5−メチル−7−ニトロ−1・2・3・4−テ
トラヒドロ−9−オキソキサンテン−2−カル
ボン酸メチルエステル: 5−メチル−1・2・3・4−テトラヒドロ−
9−オキソキサンテン−2−カルボン酸メチルエ
ステル6.80gの濃硫酸25ml中に氷冷下硝酸(d=
1.38)6mlをゆつくり滴下し、滴下後30分間撹拌
した。反応終了後反応溶液を氷水中に投入し、析
出した白色粉末を取し、水洗、風乾後氷酢酸に
より再結晶させれば融点216〜218℃(分解)を示
す白色粉末4.42g(粗収率55.6%)を得た。ニト
ロメタンにより再結晶させ融点230〜232℃(分
解)を示す5−メチル−7−ニトロ−1・2・
3・4−テトラヒドロ−9−オキソキサンテン−
2−カルボン酸メチルエステルの白色粉末を得
た。 IR(νKBr naxcm-1):1700(−COOCH3)、1635(

C=O)、1540、1370(−NO2) NMR(DMSO−d6)δ:7.82〜7.42(2H、m、Ar
−H)、3.62(3H、s、COOCH3)、3.78〜2.27
〔5H、m、(C1、C3のCH2及びC2のCH)〕、2.27
〜1.78〔2H、m(C4のCH2)〕、2.45〔3H、
s、(C5のCH3)〕 実施例 8 5−メチル−7−ニトロ−1・2・3・4−テ
トラヒドロ−9−オキソキサンテン−2−カル
ボン酸: 5−メチル−7−ニトロ−1・2・3・4−テ
トラヒドロ−9−オキソキサンテン−2−カルボ
ン酸メチルエステル4.01gを水酸化ナトリウム
0.56gとともにメタノール80ml及び水20mlの混合
溶媒中に加え、2時間加熱還流撹拌後、減圧下に
溶媒を留去し、残渣に熱水を加え溶解した。過
後、液を濃塩酸にて酸性化し、析出した沈澱を
取、水洗後風乾し、酢酸中より再結晶し、融点
259〜260℃(分解)白色葉状晶の5−メチル−7
−ニトロ−1・2・3・4−テトラヒドロ−9−
オキソキサンテン−2−カルボン酸1.91g(収率
50.0%)を得た。 IR(νKBr naxcm-1):1710(−COOH)、1640(−

=O)、1540、1380(−NO2) 元素分析(C15H13NO6として): C H N 計算値(%) 59.40 4.32 4.62 実測値(%) 59.21 4.16 4.78
[Table] As is clear from the results, the compound of the present invention has an anti-allergic effect that is 10 times more effective than that of the comparative compound. As mentioned above, the compound of the present invention is useful as a medicine in itself, but if it is further dehydrogenated, it can also be converted into a xanthene derivative having antiallergic and asthmatic effects. Next, examples will be given and explained. Example 1 7-nitro-1,2,3,4-tetrahydro-
9-oxoxanthene-2-carboxylic acid methyl ester: 5.17 g of 1,2,3,4-tetrahydro-9-oxoxanthene-2-carboxylic acid methyl ester
5 ml of nitric acid (d=1.38) was slowly added dropwise to 20 ml of concentrated sulfuric acid under ice cooling, and the mixture was stirred for 30 minutes. After the reaction was completed, the reaction solution was poured into ice water and extracted with chloroform. This extract was washed with diluted sodium bicarbonate solution and further washed with pure water. After drying over magnesium sulfate, the solvent was distilled off and the residue was recrystallized from nitromethane to give pale yellow prismatic crystals of 7-nitro-1,2,3,4-tetrahydro-9-oxoxanthene-2 with a melting point of 163.5-165°C. -7.40 g (yield 61.0%) of carboxylic acid methyl ester was obtained. IR (ν KBr nax cm -1 ): 1730 (-COO), 1640 (-
C=
O), 1520, 1340 ( -NO2 ) NMR ( CDCl3 ) δ: 8.95 (1H, d, J=3Hz, C8
-H), 8.48, 8.32 (1H, d×2, J=3Hz,
C 6 −H), 7.45 (1H, t, J=8Hz, C 5
H), 3.74 (3H, s, COOCH 3 ), 3.06-2.50
[5H, m, (CH 2 of C 1 and C 3 and CH of C 2 )],
2.50-1.67 [2H, m, ( CH2 of C4 ) ] Elemental analysis value (as C15H13NO6 ): CHN Calculated value (%) 59.40 4.32 4.62 Actual value (%) 59.43 4.35 4.37 Example 2 7-nitro-1,2,3,4-tetra-9-oxoxanthene-2-carboxylic acid: 7-nitro-1,2,3,4-tetrahydro-
10.30 g of 9-oxoxanthene-2-carboxylic acid methyl ester was dissolved in 120 ml of methanol and 40 ml of water with 1.60 g of sodium hydroxide, and 2
After heating and stirring under reflux for a period of time, the solvent was distilled off under reduced pressure, water was added to the residue, and the mixture was heated. The precipitated crystals produced by acidifying this solution with hydrochloric acid were collected, washed with water, air-dried, and then recrystallized from glacial acetic acid.
7-Nitro in yellow prism crystals showing 257.5℃
5.20 g (yield 52.9%) of 1,2,3,4-tetrahydro-9-oxoxanthene-2-carboxylic acid was obtained. IR (ν KBr nax cm -1 ): 1740 (-COOH), 1620 (C
=
O), 1520, 1340 (-NO 2 ) Elemental analysis value (as C 14 H 11 NO 6 ); C H N Calculated value (%) 58.13 3.83 4.84 Actual value (%) 58.00 3.73 4.57 Example 3 7-cyano- 1,2,3,4-tetrahydro-
9-oxoxanthene-2-carboxylic acid: 7-bromo-1,2,3,4-tetrahydro-
9-oxoxanthene-2-carboxylic acid 22.62g
12.54 g of cuprous cyanide was added to 120 ml of N-methyl-2-pyrrolidone solution, stirred at 190°C for 2 hours, and after cooling, 49 g of ferric chloride, 12 ml of concentrated hydrochloric acid, and water were added.
73.5 ml of the mixed solution was added, stirred at 80°C for 30 minutes, and left overnight. The precipitate was washed with water, air-dried, and then recrystallized from dimethylformamide-ether to give a melting point of 274~
7-cyano-1, 2, white foliate crystals showing temperature of 276℃
3,4-tetrahydro-9-oxoxanthene-
15.30 g (yield: 81.3%) of 2-carboxylic acid was obtained. IR (ν KBr nax cm -1 ): 2220 (-CN), 1690 (-
COOH), 1630 (-C=O) Elemental analysis value (as C 15 H 11 NO 4 ): C H N Calculated value (%) 66.91 4.12 5.20 Actual value (%) 66.45 4.16 5.42 MS (m/e): 269 [M + ] Example 4 1,2,3,4-tetrahydro-9-oxoxanthene-2,7-dicarboxylic acid: 7-cyano-1,2,3,4-tetrahydro-
8.08 g of 9-oxoxanthene-2-carboxylic acid was added to 300 ml of a mixture of water, sulfuric acid and acetic acid (1:1:1), stirred under reflux for 2 hours, allowed to cool, and 300 ml of water was added. The precipitated white precipitate was collected, washed with water, air-dried, and then recrystallized from dimethylformamide-water to obtain 6.82 g of 1,2,3,4-tetrahydro-9-oxoxanthene-2,7-carboxylic acid in the form of a white powder ( Yield: 79.0%). IR (ν KBr nax cm -1 ): 1710 (-COOH), 1630 (-
C
=O) Elemental analysis value (as C 15 H 12 O 6 ): C H Calculated value (%) 62.50 4.20 Actual value (%) 62.19 4.17 MS (m/e): 288 [M + ] Example 5 5-methyl -1,2,3,4-tetrahydro-
9-oxoxanthene-2-carboxylic acid methyl ester: (i) 76.3 g of 3-methylsalicylic acid in acetic anhydride solution
0.5 g of concentrated sulfuric acid was added to 160 ml and stirred at 100°C for 3 hours. After the reaction was completed, the reaction solution was poured into ice water and extracted with chloroform. This extract was washed with water, dried over magnesium sulfate, and the remaining oil after distilling off the solvent was crystallized from benzene.
71.3 g (yield 73.3%) of 3-methylacetylsalicylic acid in the form of white needle-like crystals exhibiting a temperature of 112 to 113.5°C was obtained. IR (ν KBr nax cm -1 ): 1760 (-COOH), 1690 (

COO), 1230 (−COO) NMR (CDCl 3 ) δ: 11.0 (1H, s, COOH),
8.06~7.78 (1H, m, Ar-H), 7.60~7.03
(2H, m, Ar-H), 2.36 [3H, s, (C 3
CH 3 )], 2.26 (3H, s, -OCOCH 3 ) (ii) 300 ml of anhydrous chloroform containing 64.6 g of 3-methylacetylsalicylic acid was cooled to below 0°C, first 33.7 g of triethylamine was added dropwise, and further
At 10°C, 36.1 g of ethyl chloroformate and then 69.7 g of methyl 1-pyrrolidinocyclohexene-4-carboxylate were added dropwise, followed by stirring for 4 hours and gradually returning to room temperature. The solvent was distilled off under reduced pressure, 250 ml of pyridine and 60 ml of water were added to the residue, and the mixture was heated and stirred under reflux for 1 hour, and the solvent was distilled off again. Furthermore, 600 ml of water was added to the residue, and after standing overnight, the precipitate was collected and washed with methanol to obtain a pale yellow powder. This was crystallized in methanol and the melting point was
5-Methyl- as white needle-like crystals at 152-153℃
1,2,3,4-tetrahydro-9-oxoxanthene-2-carboxylic acid methyl ester 48.5
g (yield 53.5%) was obtained. IR (ν KBr nax cm -1 ): 1720 (-COO), 1640 (
-C
=O) NMR ( CDCl3 ) δ: 8.02-7.97 (1H, m, Ar-
H), 7.62-7.10 (2H, m, Ar-H), 3.77
(3H, s, COOMe), 3.26-1.67 [7H, m,
(CH2 of C1 , C3 , C4 and CH2 of C2)], 2.43
[3H, s, (C 5 CH 3 )] Elemental analysis value (as C 16 H 16 O 4 ): C H Calculated value (%) 70.57 5.92 Actual value (%) 70.83 5.88 MS (m/e): 272 [M + ] Example 6 5-methyl-1,2,3,4-tetrahydro-
9-oxoxanthene-2-carboxylic acid: 5-methyl-1,2,3,4-tetrahydro-
27.2 g of 9-oxoxanthene-2-carboxylic acid methyl ester was dissolved in 200 ml of methanol along with 5.2 g of sodium hydroxide, and after heating and stirring under reflux for 2 hours, the solvent was distilled off under reduced pressure, and the residue was dissolved in water.
passed. This solution was acidified with 10% hydrochloric acid, and the precipitated white precipitate was collected, washed with water, air-dried, and then recrystallized from acetic acid to form pale yellow prismatic crystals of 5-methyl-1,2,3 with a melting point of 238.5 to 240°C.・4-tetrahydro-9-oxoxanthene-2-carboxylic acid 21.9
g (yield 84.7%). IR (ν KBr nax cm -1 ): 1730 (-COOH) NMR (CMSO-d 6 ) δ: 7.97-7.11 (3H, m, Ar
−H), 3.04 to 1.43 [7H, m, C 1 , C 3 , C 4
CH 2 and C 2 CH)], 2.31 (3H, s, CH 3 ) Elemental analysis value (as C 15 H 14 O 4 ): C H Calculated value (%) 69.75 5.46 Actual value (%) 69.79 5.43 MS ( m/e): 258 [M + ], 213 [M-COOH] Example 7 5-Methyl-7-nitro-1,2,3,4-tetrahydro-9-oxoxanthene-2-carboxylic acid methyl ester: 5-methyl-1,2,3,4-tetrahydro-
Nitric acid (d=
1.38) 6 ml was slowly added dropwise and stirred for 30 minutes after the addition. After the reaction is complete, the reaction solution is poured into ice water, the precipitated white powder is collected, washed with water, air-dried, and then recrystallized with glacial acetic acid to obtain 4.42 g of white powder with a melting point of 216-218°C (decomposition) (crude yield). 55.6%). 5-Methyl-7-nitro-1,2, which shows a melting point of 230-232°C (decomposition) when recrystallized with nitromethane
3,4-tetrahydro-9-oxoxanthene-
A white powder of 2-carboxylic acid methyl ester was obtained. IR (ν KBr nax cm -1 ): 1700 (-COOCH 3 ), 1635 (

C=O), 1540, 1370 ( -NO2 ) NMR (DMSO- d6 ) δ: 7.82-7.42 (2H, m, Ar
-H), 3.62 (3H, s, COOCH 3 ), 3.78-2.27
[5H, m, (C 1 , CH 2 of C 3 and CH of C 2 )], 2.27
~1.78 [2H, m (C 4 CH 2 )], 2.45 [3H,
s, ( CH3 at C5 )] Example 8 5-Methyl-7-nitro-1,2,3,4-tetrahydro-9-oxoxanthene-2-carboxylic acid: 5-methyl-7-nitro-1・4.01g of 2,3,4-tetrahydro-9-oxoxanthene-2-carboxylic acid methyl ester was dissolved in sodium hydroxide.
The mixture was added together with 0.56 g to a mixed solvent of 80 ml of methanol and 20 ml of water, heated under reflux and stirred for 2 hours, the solvent was distilled off under reduced pressure, and hot water was added to the residue to dissolve it. After filtration, the solution was acidified with concentrated hydrochloric acid, the precipitate was collected, washed with water, air-dried, recrystallized from acetic acid, and the melting point
259-260℃ (decomposition) White foliate crystals of 5-methyl-7
-Nitro-1,2,3,4-tetrahydro-9-
1.91 g of oxoxanthene-2-carboxylic acid (yield
50.0%). IR (ν KBr nax cm -1 ): 1710 (-COOH), 1640 (-
C
=O), 1540, 1380 (-NO 2 ) Elemental analysis (as C 15 H 13 NO 6 ): C H N Calculated value (%) 59.40 4.32 4.62 Actual value (%) 59.21 4.16 4.78

Claims (1)

【特許請求の範囲】 1 一般式 〔式中、R1はニトロ基、カルボキシル基またはシ
アノ基を、R2は水素原子または低級アルキル基
を示す〕 で表わされるテトラヒドロキサンテン−2−カル
ボン酸誘導体。
[Claims] 1. General formula [In the formula, R 1 represents a nitro group, a carboxyl group or a cyano group, and R 2 represents a hydrogen atom or a lower alkyl group] A tetrahydroxanthene-2-carboxylic acid derivative represented by the following formula.
JP10037278A 1978-08-17 1978-08-17 Tetrahydroxanthene-2-carboxylic derivative Granted JPS5527163A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP10037278A JPS5527163A (en) 1978-08-17 1978-08-17 Tetrahydroxanthene-2-carboxylic derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP10037278A JPS5527163A (en) 1978-08-17 1978-08-17 Tetrahydroxanthene-2-carboxylic derivative

Publications (2)

Publication Number Publication Date
JPS5527163A JPS5527163A (en) 1980-02-27
JPS625153B2 true JPS625153B2 (en) 1987-02-03

Family

ID=14272202

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10037278A Granted JPS5527163A (en) 1978-08-17 1978-08-17 Tetrahydroxanthene-2-carboxylic derivative

Country Status (1)

Country Link
JP (1) JPS5527163A (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5239677A (en) * 1975-09-22 1977-03-28 Kowa Co Preparation of xanthene derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5239677A (en) * 1975-09-22 1977-03-28 Kowa Co Preparation of xanthene derivatives

Also Published As

Publication number Publication date
JPS5527163A (en) 1980-02-27

Similar Documents

Publication Publication Date Title
JPS623152B2 (en)
US3484445A (en) Derivatives of chromone-2-carboxylic acid
JPH03181465A (en) Quinoline derivative
GB1580110A (en) Substituted tetrazole compounds
JPS5921682A (en) Manufacture of 4-hydroxy-2-methyl-n-2-pyridyl- 2h-1,2-benzothiazine-3-carboxamide-1,1-dioxide
JPH0433793B2 (en)
EP0349902A2 (en) Processes for the preparation of morniflumate and analogous compounds
JPS625153B2 (en)
US5519043A (en) Fluorenyl derivatives
US5472973A (en) Fluorenyl derivatives as anti-inflammatory agents
JPH033658B2 (en)
JP3901239B2 (en) Arylalkane derivatives
US4568690A (en) 1-Methyl-5-p-methylbenzoylpyrrole-2-acetamidoacetanilides with antiinflammatory, analgesic, antipyretic and anti-platelet aggregant activity
JPH07121933B2 (en) Dihydrobenzofuranone derivative
JPS6056130B2 (en) Novel salicylic acid derivatives
US2705232A (en) Ternorcholanylthiazoles
JPH0710863B2 (en) Novel derivative of 4-OH quinolinecarboxylic acid substituted at position 2 with an etherifiable or esterifiable dihydroxy group, a process for its preparation and its use as a medicament
JPS6031823B2 (en) Method for producing carbazole derivatives
JPS6136754B2 (en)
Hager et al. Synthesis of Stilbenecarboxylic Acids
JPS6148513B2 (en)
US3329701A (en) Cyanobenzophenones
FI68231C (en) ANALOGIFICATION OF THREATED BOLIMIMIDAZOLE-2 DERIVATIVES
JPS6148514B2 (en)
US3499027A (en) Intermediates for preparing certain 1,4-benzodiazepin-2-(1h)-ones